Effects of body weight regain on leptin levels: A systematic review and meta-analysis.

BMI Leptin Systematic review, hormonal changes? Weight regain

Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
12 2021
Historique:
received: 27 02 2021
revised: 14 07 2021
accepted: 15 07 2021
pubmed: 5 8 2021
medline: 19 2 2022
entrez: 4 8 2021
Statut: ppublish

Résumé

There are different changes observed before and after diet therapy, and also after weight regain. However, there is not sufficient information regarding weight regain and hormonal changes. The purpose of this study was to review the connection between weight regain and leptin concentration levels. MEDLINE, SCOPUS, Web of Science, and the Cochrane Library were searched for interventional articles published from January 1, 1980, to June 30, 2020. Randomized clinical trials with parallel or cross over design assessing leptin concentrations at the baseline and at the end of study were reviewed. Two independent reviewers extracted data related to study design, year of publication, country, age, gender, body mass index (BMI), duration of the following up period and mean ± SD of other intended variables. Four articles were included, published between 2004 and 2016. Three of them were conducted in the US and one of them in Netherland. Sample size of the studies ranged between 25 and 148 participants. The range of following up period was from13 to 48 weeks. The age range of participants was from 34 to 44 years. Our analysis shows that weight regain could reduce leptin levels, but this change is not statistically significant. This review suggests that weight regain may induce a non-significant reduction in leptin level. However, the limited number and great heterogeneity between the included studies may affect the presented results and there are still need to well-designed, large population studies to determine the relationship between weight regain and leptin levels.

Sections du résumé

BACKGROUND
There are different changes observed before and after diet therapy, and also after weight regain. However, there is not sufficient information regarding weight regain and hormonal changes.
PURPOSE
The purpose of this study was to review the connection between weight regain and leptin concentration levels.
METHODS
MEDLINE, SCOPUS, Web of Science, and the Cochrane Library were searched for interventional articles published from January 1, 1980, to June 30, 2020. Randomized clinical trials with parallel or cross over design assessing leptin concentrations at the baseline and at the end of study were reviewed. Two independent reviewers extracted data related to study design, year of publication, country, age, gender, body mass index (BMI), duration of the following up period and mean ± SD of other intended variables.
RESULTS
Four articles were included, published between 2004 and 2016. Three of them were conducted in the US and one of them in Netherland. Sample size of the studies ranged between 25 and 148 participants. The range of following up period was from13 to 48 weeks. The age range of participants was from 34 to 44 years. Our analysis shows that weight regain could reduce leptin levels, but this change is not statistically significant.
CONCLUSION
This review suggests that weight regain may induce a non-significant reduction in leptin level. However, the limited number and great heterogeneity between the included studies may affect the presented results and there are still need to well-designed, large population studies to determine the relationship between weight regain and leptin levels.

Identifiants

pubmed: 34344588
pii: S1043-4666(21)00233-7
doi: 10.1016/j.cyto.2021.155647
pii:
doi:

Substances chimiques

Leptin 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

155647

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Najme Rostami Rayeni (N)

Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

Hadi Abdollahzad (H)

Department of Nutritional Science, School of Nutritional Science and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Pooya Alibakhshi (P)

Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Mojgan Morvaridzadeh (M)

Songhor Healthcare Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Hafez Heydari (H)

Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Afsaneh Dehnad (A)

Department of English Language, School of Health Management and Information Sciences, Center for Educational Research in Medical Sciences (CERMS), Iran University of Medical Sciences, Iran. Electronic address: dehand.a@iums.ac.ir.

Masoud Khorshidi (M)

Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; Pediatric Gastroenterology, Hepatology and Nutrition Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Azimeh Izadi (A)

Iran Football Medical Assessment and Rehabilitation Center (IFMARC), Tehran, Iran; Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Farzad Shidfar (F)

Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. Electronic address: shidfar.f@iums.ac.ir.

M Dulce Estêvão (M)

Universidade do Algarve, Escola Superior de Saúde, Campus de Gambelas, Faro, Portugal. Electronic address: mestevao@ualg.pt.

Amirhosein Omidi (A)

Songhor Healthcare Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Javad Heshmati (J)

Songhor Healthcare Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: javad.heshmati@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH